Sera Prognostics (NASDAQ:SERA) CFO Austin Aerts Sells 6,069 Shares

Sera Prognostics, Inc. (NASDAQ:SERA) CFO Austin Aerts sold 6,069 shares of Sera Prognostics stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $1.90, for a total value of $11,531.10. Following the completion of the sale, the chief financial officer directly owned 265,471 shares of the company’s stock, valued at $504,394.90. The trade was a 2.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Austin Aerts also recently made the following trade(s):

• On Wednesday, March 11th, Austin Aerts sold 1,019 shares of Sera Prognostics stock. The shares were sold at an average price of $2.04, for a total value of $2,078.76.
• On Monday, March 9th, Austin Aerts sold 674 shares of Sera Prognostics stock. The stock was sold at an average price of $1.96, for a total transaction of $1,321.04.

Sera Prognostics Trading Up 6.5%

NASDAQ SERA traded up $0.13 on Friday, hitting $2.12. 26,392 shares of the company traded hands, compared to its average volume of 56,926. The business’s 50 day moving average price is $2.76 and its 200-day moving average price is $3.05. The company has a market capitalization of $81.82 million, a price-to-earnings ratio of -2.75 and a beta of 1.01. Sera Prognostics, Inc. has a 52-week low of $1.37 and a 52-week high of $4.20.

Sera Prognostics News Roundup

Here are the key news stories impacting Sera Prognostics this week:

• Neutral Sentiment: Coverage piece contrasting Sera and Revvity — a recent article compares SERA to Revvity (RVTY), which may influence investor attention or comparisons across healthcare peers but contains no company-specific fundamental disclosure. Contrasting Sera Prognostics (NASDAQ:SERA) and Revvity (NYSE:RVTY)
• Negative Sentiment: CEO Zhenya Lindgardt sold a total of 25,612 shares across filings (22,639 shares at $1.90 on Mar 10 and 2,973 shares at $2.04 on Mar 11), raising roughly $49k; the filings show a near 3% and 0.4% reduction in holdings respectively. Significant CEO selling can weigh on sentiment for a small-cap biotech. SEC Filing – Lindgardt Sales
• Negative Sentiment: CFO Austin Aerts sold 7,088 shares across two trades (6,069 at $1.90 and 1,019 at $2.04), totaling roughly $13.6k and reducing his stake ~2.2% and 0.38% in filings. Insider sales by senior finance officers can signal near-term liquidity-taking and may be viewed unfavorably in thinly traded names. SEC Filing – Aerts Sales
• Negative Sentiment: Other insiders (General Counsel Benjamin Jackson; John J. Boniface; Paul Kearney; Robert Gardner Harrison) executed small sales on Mar 11 (combined ~4,656 shares, ~ $9.5k). While each sale is modest, the broad pattern of multiple insiders selling within a short window can amplify investor concern about management conviction. SEC filings: Jackson Jackson Filing, Boniface Boniface Filing, Kearney Kearney Filing, Harrison Harrison Filing

Analyst Upgrades and Downgrades

SERA has been the subject of a number of recent analyst reports. Jefferies Financial Group upgraded shares of Sera Prognostics to a “strong-buy” rating in a research report on Monday, December 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Sera Prognostics in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

Hedge Funds Weigh In On Sera Prognostics

Hedge funds have recently modified their holdings of the stock. Wealth Enhancement Advisory Services LLC purchased a new position in Sera Prognostics during the fourth quarter valued at $31,000. Vanguard Personalized Indexing Management LLC purchased a new stake in Sera Prognostics in the 3rd quarter worth $38,000. Riverview Capital Advisers LLC bought a new position in shares of Sera Prognostics during the 2nd quarter valued at about $35,000. Lido Advisors LLC purchased a new position in shares of Sera Prognostics during the third quarter valued at about $68,000. Finally, Cetera Investment Advisers bought a new stake in shares of Sera Prognostics in the fourth quarter worth about $74,000. Hedge funds and other institutional investors own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.